Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

Therapeutic relevance of the PP2A-B55 inhibitory kinase MASTL/Greatwall in breast cancer.

Álvarez-Fernández M, Sanz-Flores M, Sanz-Castillo B, Salazar-Roa M, Partida D, Zapatero-Solana E, Ali HR, Manchado E, Lowe S, VanArsdale T, Shields D, Caldas C, Quintela-Fandino M, Malumbres M.

Cell Death Differ. 2017 Dec 11. doi: 10.1038/s41418-017-0024-0. [Epub ahead of print]

PMID:
29229993
2.

Spectrum and Degree of CDK Drug Interactions Predicts Clinical Performance.

Chen P, Lee NV, Hu W, Xu M, Ferre RA, Lam H, Bergqvist S, Solowiej J, Diehl W, He YA, Yu X, Nagata A, VanArsdale T, Murray BW.

Mol Cancer Ther. 2016 Oct;15(10):2273-2281. Epub 2016 Aug 5.

3.

Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer.

Wardell SE, Ellis MJ, Alley HM, Eisele K, VanArsdale T, Dann SG, Arndt KT, Primeau T, Griffin E, Shao J, Crowder R, Lai JP, Norris JD, McDonnell DP, Li S.

Clin Cancer Res. 2015 Nov 15;21(22):5121-5130. doi: 10.1158/1078-0432.CCR-15-0360. Epub 2015 May 19.

4.

Molecular Pathways: Targeting the Cyclin D-CDK4/6 Axis for Cancer Treatment.

VanArsdale T, Boshoff C, Arndt KT, Abraham RT.

Clin Cancer Res. 2015 Jul 1;21(13):2905-10. doi: 10.1158/1078-0432.CCR-14-0816. Epub 2015 May 4. Review.

5.

GLI2 inhibition abrogates human leukemia stem cell dormancy.

Sadarangani A, Pineda G, Lennon KM, Chun HJ, Shih A, Schairer AE, Court AC, Goff DJ, Prashad SL, Geron I, Wall R, McPherson JD, Moore RA, Pu M, Bao L, Jackson-Fisher A, Munchhof M, VanArsdale T, Reya T, Morris SR, Minden MD, Messer K, Mikkola HK, Marra MA, Hudson TJ, Jamieson CH.

J Transl Med. 2015 Mar 21;13:98. doi: 10.1186/s12967-015-0453-9.

6.

Resistance to dual blockade of the kinases PI3K and mTOR in KRAS-mutant colorectal cancer models results in combined sensitivity to inhibition of the receptor tyrosine kinase EGFR.

Belmont PJ, Jiang P, McKee TD, Xie T, Isaacson J, Baryla NE, Roper J, Sinnamon MJ, Lee NV, Kan JL, Guicherit O, Wouters BG, O'Brien CA, Shields D, Olson P, VanArsdale T, Weinrich SL, Rejto P, Christensen JG, Fantin VR, Hung KE, Martin ES.

Sci Signal. 2014 Nov 11;7(351):ra107. doi: 10.1126/scisignal.2005516.

PMID:
25389372
7.

Combination of 4-1BB agonist and PD-1 antagonist promotes antitumor effector/memory CD8 T cells in a poorly immunogenic tumor model.

Chen S, Lee LF, Fisher TS, Jessen B, Elliott M, Evering W, Logronio K, Tu GH, Tsaparikos K, Li X, Wang H, Ying C, Xiong M, VanArsdale T, Lin JC.

Cancer Immunol Res. 2015 Feb;3(2):149-60. doi: 10.1158/2326-6066.CIR-14-0118. Epub 2014 Nov 11.

8.

Pillars article: A lymphotoxin-B-specific receptor. Science. 1994. 264: 707-710.

Crowe PD, Vanarsdale TL, Walter BN, Ware CF, Hession C, Ehrenfels B, Browning JL, Din WS, Goodwin RG, Smith CA.

J Immunol. 2014 Mar 1;192(5):2015-8. No abstract available.

9.

Antitumor Efficacy of the Dual PI3K/mTOR Inhibitor PF-04691502 in a Human Xenograft Tumor Model Derived from Colorectal Cancer Stem Cells Harboring a PIK3CA Mutation.

Fang DD, Zhang CC, Gu Y, Jani JP, Cao J, Tsaparikos K, Yuan J, Thiel M, Jackson-Fisher A, Zong Q, Lappin PB, Hayashi T, Schwab RB, Wong A, John-Baptiste A, Bagrodia S, Los G, Bender S, Christensen J, Vanarsdale T.

PLoS One. 2013 Jun 27;8(6):e67258. doi: 10.1371/journal.pone.0067258. Print 2013.

10.

Combined gemcitabine and CHK1 inhibitor treatment induces apoptosis resistance in cancer stem cell-like cells enriched with tumor spheroids from a non-small cell lung cancer cell line.

Fang DD, Cao J, Jani JP, Tsaparikos K, Blasina A, Kornmann J, Lira ME, Wang J, Jirout Z, Bingham J, Zhu Z, Gu Y, Los G, Hostomsky Z, Vanarsdale T.

Front Med. 2013 Dec;7(4):462-76. doi: 10.1007/s11684-013-0270-6. Epub 2013 Jul 2.

PMID:
23820871
11.

Development of a colon cancer GEMM-derived orthotopic transplant model for drug discovery and validation.

Martin ES, Belmont PJ, Sinnamon MJ, Richard LG, Yuan J, Coffee EM, Roper J, Lee L, Heidari P, Lunt SY, Goel G, Ji X, Xie Z, Xie T, Lamb J, Weinrich SL, VanArsdale T, Bronson RT, Xavier RJ, Vander Heiden MG, Kan JL, Mahmood U, Hung KE.

Clin Cancer Res. 2013 Jun 1;19(11):2929-40. doi: 10.1158/1078-0432.CCR-12-2307. Epub 2013 Feb 12.

12.

PF-03732010: a fully human monoclonal antibody against P-cadherin with antitumor and antimetastatic activity.

Zhang CC, Yan Z, Zhang Q, Kuszpit K, Zasadny K, Qiu M, Painter CL, Wong A, Kraynov E, Arango ME, Mehta PP, Popoff I, Casperson GF, Los G, Bender S, Anderes K, Christensen JG, VanArsdale T.

Clin Cancer Res. 2010 Nov 1;16(21):5177-88. doi: 10.1158/1078-0432.CCR-10-1343. Epub 2010 Sep 9.

13.

Structure-based design of novel human Pin1 inhibitors (I).

Guo C, Hou X, Dong L, Dagostino E, Greasley S, Ferre R, Marakovits J, Johnson MC, Matthews D, Mroczkowski B, Parge H, Vanarsdale T, Popoff I, Piraino J, Margosiak S, Thomson J, Los G, Murray BW.

Bioorg Med Chem Lett. 2009 Oct 1;19(19):5613-6. doi: 10.1016/j.bmcl.2009.08.034. Epub 2009 Aug 13.

PMID:
19729306
14.

Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia.

Zhao C, Chen A, Jamieson CH, Fereshteh M, Abrahamsson A, Blum J, Kwon HY, Kim J, Chute JP, Rizzieri D, Munchhof M, VanArsdale T, Beachy PA, Reya T.

Nature. 2009 Apr 9;458(7239):776-9. doi: 10.1038/nature07737. Erratum in: Nature. 2009 Jul 30;460(7255):652.

15.

TRAF family proteins interact with the common neurotrophin receptor and modulate apoptosis induction.

Ye X, Mehlen P, Rabizadeh S, VanArsdale T, Zhang H, Shin H, Wang JJ, Leo E, Zapata J, Hauser CA, Reed JC, Bredesen DE.

J Biol Chem. 1999 Oct 15;274(42):30202-8.

16.

Immunohistochemical analysis of in vivo patterns of TRAF-3 expression, a member of the TNF receptor-associated factor family.

Krajewski S, Zapata JM, Krajewska M, VanArsdale T, Shabaik A, Gascoyne RD, Reed JC.

J Immunol. 1997 Dec 15;159(12):5841-52.

PMID:
9550380
17.

Lymphotoxin-beta receptor signaling complex: role of tumor necrosis factor receptor-associated factor 3 recruitment in cell death and activation of nuclear factor kappaB.

VanArsdale TL, VanArsdale SL, Force WR, Walter BN, Mosialos G, Kieff E, Reed JC, Ware CF.

Proc Natl Acad Sci U S A. 1997 Mar 18;94(6):2460-5.

18.

Hepatitis C virus core protein interacts with the cytoplasmic tail of lymphotoxin-beta receptor.

Matsumoto M, Hsieh TY, Zhu N, VanArsdale T, Hwang SB, Jeng KS, Gorbalenya AE, Lo SY, Ou JH, Ware CF, Lai MM.

J Virol. 1997 Feb;71(2):1301-9.

19.

Apoptosis mediated by the TNF-related cytokine and receptor families.

Ware CF, VanArsdale S, VanArsdale TL.

J Cell Biochem. 1996 Jan;60(1):47-55. Review.

PMID:
8825415
20.

The Epstein-Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family.

Mosialos G, Birkenbach M, Yalamanchili R, VanArsdale T, Ware C, Kieff E.

Cell. 1995 Feb 10;80(3):389-99.

21.

The ligands and receptors of the lymphotoxin system.

Ware CF, VanArsdale TL, Crowe PD, Browning JL.

Curr Top Microbiol Immunol. 1995;198:175-218. Review. No abstract available.

PMID:
7774281
23.

A lymphotoxin-beta-specific receptor.

Crowe PD, VanArsdale TL, Walter BN, Ware CF, Hession C, Ehrenfels B, Browning JL, Din WS, Goodwin RG, Smith CA.

Science. 1994 Apr 29;264(5159):707-10.

PMID:
8171323
24.

Production of lymphotoxin (LT alpha) and a soluble dimeric form of its receptor using the baculovirus expression system.

Crowe PD, VanArsdale TL, Walter BN, Dahms KM, Ware CF.

J Immunol Methods. 1994 Jan 12;168(1):79-89.

PMID:
8288897
25.
26.

Tumor necrosis factor (TNF) receptor expression in T lymphocytes. Differential regulation of the type I TNF receptor during activation of resting and effector T cells.

Ware CF, Crowe PD, Vanarsdale TL, Andrews JL, Grayson MH, Jerzy R, Smith CA, Goodwin RG.

J Immunol. 1991 Dec 15;147(12):4229-38.

PMID:
1661312

Supplemental Content

Loading ...
Support Center